Ken Griffin Collegium Pharmaceutical, Inc Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
BUY
$31.23 - $40.91 $1.06 Million - $1.38 Million
33,800 Added 489.86%
40,700 $1.58 Million
Q4 2023

Feb 14, 2024
BUY
$21.16 - $30.8 $146,004 - $212,520
6,900 New
6,900 $212,000
Q2 2023

Aug 14, 2023
SELL
$21.06 - $24.0 $21,060 - $24,000
-1,000 Reduced 14.93%
5,700 $122,000
Q1 2023

May 15, 2023
SELL
$23.0 - $29.88 $172,500 - $224,100
-7,500 Reduced 52.82%
6,700 $160,000
Q4 2022

Feb 14, 2023
BUY
$16.14 - $23.55 $4,842 - $7,065
300 Added 2.16%
14,200 $329,000
Q3 2022

Nov 14, 2022
SELL
$15.46 - $20.1 $10,822 - $14,070
-700 Reduced 4.79%
13,900 $223,000

Others Institutions Holding COLL

# of Institutions
231
Shares Held
39.5M
Call Options Held
104K
Put Options Held
15.4K
View Full List

About COLLEGIUM PHARMACEUTICAL, INC

COLL Quotes by TradingView
  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.1B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email